139 related articles for article (PubMed ID: 3116551)
1. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Navratil H
Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
[No Abstract] [Full Text] [Related]
2. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
3. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
[No Abstract] [Full Text] [Related]
4. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
5. Total androgen blockade for metastatic cancer of the prostate.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
[TBL] [Abstract][Full Text] [Related]
6. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
[No Abstract] [Full Text] [Related]
7. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
Fiet J; Doré JC; Gô AL; Ojasoo T; Raynaud JP
Prostate; 1993; 23(4):291-313. PubMed ID: 8259343
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
[TBL] [Abstract][Full Text] [Related]
9. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
10. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
[No Abstract] [Full Text] [Related]
11. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Hucher M; de Gery A; Bertagna C
Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
[No Abstract] [Full Text] [Related]
12. Maximal androgen blockade in prostatic cancer.
Denis L
Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
[No Abstract] [Full Text] [Related]
13. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
[No Abstract] [Full Text] [Related]
14. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
[TBL] [Abstract][Full Text] [Related]
15. Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
Namer M; Amiel J; Toubol J
Am J Clin Oncol; 1988; 11 Suppl 2():S191-6. PubMed ID: 3071952
[TBL] [Abstract][Full Text] [Related]
16. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Waxman J
Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
[No Abstract] [Full Text] [Related]
17. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
18. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and clinical studies with RU 23908 (Anandron).
Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
[No Abstract] [Full Text] [Related]
20. [Complete androgen blockage in the treatment of metastatic prostate cancer].
Matzkin H; Braf Z
Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
